Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
LNTH Stock Chart & Stats
$76.43
-$2.32(-2.39%)
At close: 4:00 PM EST
$76.43
-$2.32(-2.39%)
Day’s Range― - ―
52-Week Range$47.25 - $108.91
Previous CloseN/A
Volume177.90K
Average Volume (3M)1.05M
Market Cap
$4.94B
Enterprise Value$5.38B
Total Cash (Recent Filing)$359.12M
Total Debt (Recent Filing)$673.25M
Price to Earnings (P/E)19.2
Beta0.52
Next Earnings
Apr 30, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding64,605,896
10 Day Avg. Volume1,255,473
30 Day Avg. Volume1,046,033
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue3.49
Enterprise Value/Gross Profit5.71
Enterprise Value/Ebitda13.34
Forecast
1Y Price Target
$87.88Price Target Upside14.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)5.19
Revenue Forecast (FY)$1.45B
Bulls Say, Bears Say
Bulls Say
Alzheimer Diagnostic GrowthOngoing launch of Neuraceq combined with potential approvals of additional Alzheimer diagnostic agents creates multiple revenue drivers and offers exposure to growth in Alzheimer therapies without direct binary clinical trial risk.
Regulatory ResolutionAnalyst expects the company to resolve the manufacturing issue and secure regulatory approval because the review delay was tied to manufacturing information rather than clinical safety or effectiveness concerns.
Reimbursement And PricingApproval of a new F18 PSMA PET agent increases confidence that transitional pass-through reimbursement could be achieved for a next-generation PSMA imaging product, which would support stronger early pricing and an improved product mix for the Pylarify franchise.
Bears Say
Execution Risk & VolatilityRegulatory delays and guidance below consensus push expected benefits from new formulations and pipeline assets further into the future, increasing execution risk and the potential for share-price volatility.
Guidance And CompetitionRevenue guidance implies a decline driven largely by increased competition for core products, which has prompted more cautious analyst ratings and limits upside in the current valuation outlook.
Pricing PressureManagement identified persistent pricing pressure that is expected to outweigh modest volume gains, creating uncertainty for flagship product revenue and overall top-line stability.
Lantheus News
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $47.25 and its highest was $108.91 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $4.94B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Apr 30, 2026 which is in 39 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Feb 26, 2026. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.194 by $0.476.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.23.
How many shares outstanding does Lantheus have?
Lantheus has 64,605,896 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.67 in its last earnings report, beating expectations of $1.194. Following the earnings report the stock price went down -0.383%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in LNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantheus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.88 (14.98% Upside)
$87.88 (14.98% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.68%
12-Months-Change
Fundamentals
Return on Equity
20.58%
Trailing 12-Months
Asset Growth
10.53%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
LNTH Company Deck
LNTH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced / Neutral: The call highlighted meaningful strategic progress — acquisitions (Neuraceq, OCTEVY candidate), a broadened radiodiagnostic pipeline, strong product positions (PYLARIFY volumes, DEFINITY market share), multiple near-term regulatory milestones, and a clear commercialization plan targeting 2027 growth. However, near-term pressures are material: PYLARIFY revenue decline and pricing headwinds, gross margin compression (~289 bps YoY), Q4 cash-flow and free-cash-flow deterioration, and notable one-time integration and litigation costs. Management is taking prudent, deliberate steps (divestiture of SPECT, focusing capital on diagnostics, launch-readiness investments) which support a constructive medium-to-long-term outlook, but the near-term financial headwinds and execution/timing risks balance the positives.View all LNTH earnings summariesLNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$87.88
▲(14.98% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
Currently, No data available
---